CN102443044B - N-substituted ester-containing phenyl-14 Beta-aminomethyl epitriptolide derivatives, preparation method and use thereof - Google Patents
N-substituted ester-containing phenyl-14 Beta-aminomethyl epitriptolide derivatives, preparation method and use thereof Download PDFInfo
- Publication number
- CN102443044B CN102443044B CN2010105076526A CN201010507652A CN102443044B CN 102443044 B CN102443044 B CN 102443044B CN 2010105076526 A CN2010105076526 A CN 2010105076526A CN 201010507652 A CN201010507652 A CN 201010507652A CN 102443044 B CN102443044 B CN 102443044B
- Authority
- CN
- China
- Prior art keywords
- epitriptolide
- aminomethyl
- phenyl
- compound
- methoxycarbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- UNQZXYVISZUVFZ-DVEUAEDNSA-N CC(C)[C@]1([C@@](CNc(ccc(O)c2)c2C(OC)=O)([C@]23O[C@H]2C2)O)[U][C@H]1[C@@H]1O[C@]31[C@@](C)(CC1)[C@@H]2C(CO2)=C1C2=O Chemical compound CC(C)[C@]1([C@@](CNc(ccc(O)c2)c2C(OC)=O)([C@]23O[C@H]2C2)O)[U][C@H]1[C@@H]1O[C@]31[C@@](C)(CC1)[C@@H]2C(CO2)=C1C2=O UNQZXYVISZUVFZ-DVEUAEDNSA-N 0.000 description 1
- JRLMORJQWUCKFI-XESGGTJHSA-N CC(C)[C@]1([C@@](CO)([C@]23O[C@H]2C2)O)O[C@H]1[C@@H]1O[C@]31[C@@](C)(CC1)[C@@H]2C(CO2)=C1C2=O Chemical compound CC(C)[C@]1([C@@](CO)([C@]23O[C@H]2C2)O)O[C@H]1[C@@H]1O[C@]31[C@@](C)(CC1)[C@@H]2C(CO2)=C1C2=O JRLMORJQWUCKFI-XESGGTJHSA-N 0.000 description 1
- LDBRUDBYFNZWRU-KLNZJBFLSA-N CC(C)[C@]1([C@@]([C@]23O[C@H]2C2)(O)[Si](C)(C)OC(C)C)O[C@H]1[C@@H]1O[C@]31[C@@](C)(CC1)[C@@H]2C(CO2)=C1C2=O Chemical compound CC(C)[C@]1([C@@]([C@]23O[C@H]2C2)(O)[Si](C)(C)OC(C)C)O[C@H]1[C@@H]1O[C@]31[C@@](C)(CC1)[C@@H]2C(CO2)=C1C2=O LDBRUDBYFNZWRU-KLNZJBFLSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Nc1ccccc1 Chemical compound Nc1ccccc1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides tripterygium diterpenoid derivatives represented in the general formula (II-7), salts acceptable on pharmacology, a preparation method, a pharmaceutical composition and use thereof in preparing medicine for treating tumors, in particular ovarian cancer or prostatic cancer.
Description
Technical field
The present invention relates to field of medicaments, in particular to a class tripterygium wilfordii diterpenes diterpenoids lactones derivative and pharmacy acceptable salt thereof, its preparation method with and application in the medicine for the preparation for the treatment of tumour, particularly genital system tumor.
Background technology
Trypterygine, the popular name Graceful Jessamine Herb, be Celastraceae (Celastraceae) Thunder God Calamus bejuco, is that the resource that has of China is than a more rich kind of plant.Thunder God Calamus (Tripterygium) plant has four kinds, be trypterygine (Tripterygium wilfordii Hook f.), Tripterygium hypoglaucum (Tripterygium hypoglaucum Levl.Hutch), northeast trypterygine (black climing) (Tripterygium regelii Sprague et Takeda) and Cangshan trypterygine (Tripterygium forretii Dicls), in China, distribution all arranged.Trypterygine is recorded the earliest in " Dragon Lord book on Chinese herbal medicine warp ", and its main chemical compositions has diterpene, triterpene, sesquiterpene, alkaloid etc., from tripterygium plant, has isolated so far nearly 200 kinds of compound.The research that recent two decades comes shows that it has antitumor, anti-inflammatory, immunosuppression, antifertility, the various active such as antibiotic.
The trypterygine plant is in the existing history for many years of tumour that is used for the treatment of among the people, and wherein one of activeconstituents is triptolide.Triptolide, except obtaining antitumor action research widely, also once entered clinical trial, was used for the treatment of leukemia, but the larger toxic side effect of triptolide, too narrow treatment window, limited it in clinical middle application.The structure of modification of triptolide was confined in the introduction of water soluble group mostly in the past, and there is no essence on agent structure and change.After this class prodrug enters in body, by after hydrolysis or metabolism, still changing triptolide into and bring into play in vivo drug action, this has just determined that they can not fundamentally improve the toxic side effect of triptolide.Therefore, Pharmaceutical Chemists expect triptolide to be transform as always there is good aqueous solubility, high reactivity, hypotoxic antitumor drug candidate.
Summary of the invention
The inventor is by the further investigation to the triptolide structure activity relationship, its structure has been carried out being different to transformation and the modification of prior art, obtained the tripterygium wilfordii diterpenes diterpenoids lactones derivative of a collection of novel texture, mainly to introduce a series of ester group or carboxylic acid and metal carboxylate aniline small molecules side chains of containing in the C14 position, but also the C14 β-OH that will in the past think essential groups transform C14 α-OH as, thereby a series of derivatives have been obtained, and provide the preparation method of this analog derivative, external genital system tumor suppresses experiment and shows that this analog derivative has good antitumour activity, the propagation that can effectively suppress the genital system tumor cell.And, due to the introducing of metal carboxylate small molecules side chain, the water-soluble of this analog derivative will be improved greatly.
An object of the present invention is to provide novel tripterygium wilfordii diterpenes diterpenoids lactones derivative or its pharmacy acceptable salt of a class as shown in general formula (II-7).
Another object of the present invention is to provide the preparation method of a kind of described tripterygium wilfordii diterpenes diterpenoids lactones derivative or its pharmacy acceptable salt.
Another purpose of the present invention is to provide a kind of pharmaceutical composition for the treatment of tumour, and it comprises one or more described tripterygium wilfordii diterpenes diterpenoids lactones derivatives or its pharmacy acceptable salt and the pharmaceutically acceptable auxiliary material for the treatment of significant quantity.
A further object of the present invention is to provide described tripterygium wilfordii diterpenes diterpenoids lactones derivative or the purposes of its pharmacy acceptable salt in the medicine for the preparation for the treatment of tumour, particularly genital system tumor, especially ovarian cancer or prostate cancer.
According to an aspect of the present invention, provide the tripterygium wilfordii diterpenes diterpenoids lactones derivative shown in following general formula (II-7) or its pharmacy acceptable salt:
Wherein,
M means Na, K, H or R;
By one-(CH
2)
nthe phenyl that the COOM group replaces is not necessarily replaced by one or more substituting group, described substituting group be F, Cl, Br ,-(CH
2)
ncOOM, R ,-CF
3,-NO
2,-CN ,-NH
2,-NHR ,-NRR ' ,-NHCOR ,-NHCONHR ,-NHCONRR ' ,-NHCO (CH
2)
nnH
2,-NHSO
2r ,-OH ,-OR ,-OCOR ,-OCO (CH
2)
nnH
2,-OCONHR ,-OCONRR ' ,-OSO
2r ,-COR ,-CONHR ,-CONRR ' ,-CO (CH
2)
nnH
2,-SO
2nH
2,-SO
2nHR ,-SO
2nRR ' or-S (O)
er, the integer that wherein n is 0-6, e is 0,1,2 or 3;
R
2, R
3be H, C independently of one another
1-C
10straight or branched alkyl, C
2-C
10straight or branched thiazolinyl, C
3-C
10cycloalkyl ,-COR or-S (O)
ir, wherein i is 1 or 2; Preferably, R
2and R
3be H simultaneously, or R
2and R
3in one for H, another is not H;
Wherein, R, R ' are identical or different C
1-C
10straight or branched alkyl, C
2-C
10straight or branched thiazolinyl, C
3-C
10cycloalkyl, phenyl, thienyl, furyl, pyridyl or pyrryl; Preferably, R, R ' are identical or different C
1-C
4straight or branched alkyl, C
2-C
4straight or branched thiazolinyl, C
3-C
5cycloalkyl, phenyl, thienyl, furyl, pyridyl or pyrryl.
More preferably, tripterygium wilfordii diterpenes diterpenoids lactones derivative of the present invention or its pharmacy acceptable salt are:
(7-1) (14S)-14 β-N-(2 '-methoxycarbonyl phenyl)-aminomethyl Epitriptolide (LLDT-221)
(7-2) (14S)-14 β-N-(3 '-methoxycarbonyl phenyl)-aminomethyl Epitriptolide (LLDT-222)
(7-3) (14S)-14 β-N-(3 '-methoxycarbonyl-4 '-hydroxy phenyl)-aminomethyl Epitriptolide (LLDT-223)
(7-4) (14S)-14 β-N-(2 '-methoxycarbonyl-4 '-hydroxy phenyl)-aminomethyl Epitriptolide (LLDT-224)
(7-5) (14S)-14 β-N-(3 '-amino-5 '-the methoxycarbonyl phenyl)-aminomethyl Epitriptolide (LLDT-225)
(7-6) (14S)-14 β-N-(2 '-methoxycarbonyl-4 '-fluorophenyl)-aminomethyl Epitriptolide (LLDT-232)
(7-7) (14S)-14 β-N-(2 '-hydroxyl-4 '-the methoxycarbonyl phenyl)-aminomethyl Epitriptolide (LLDT-233)
(7-8) (14S)-14 β-N-(2 '-hydroxyl-5 '-the methoxycarbonyl phenyl)-aminomethyl Epitriptolide (LLDT-234)
As shown in reaction stream formula (II-7), the invention provides the preparation method of tripterygium wilfordii diterpenes diterpenoids lactones derivative shown in general formula (II-7), the method is carried out as follows:
Reaction stream formula (II-7)
(1) take Triptonide LLDT-1 as initiator, in aprotic polar solvent, utilize chloromethyl dimethyl isopropoxy silane and reactive magnesium to generate the C14 position carbonyl of attack triptolide after Grignard reagent and obtain compound (2),
(2) the thick product of step (1) gained can, without separation, directly generate dihydroxyl compound (3) under the oxygenizement of hydrogen peroxide;
(3) compound (3) is oxidized to compound (4) under the effect of oxygenant;
(4) by compound (4) and amino benzenes compounds
under the effect of sodium triacetoxy borohydride, reductive amination process occurs, generate the compound shown in general formula (II-7-i), at amino benzenes compounds
in, by one-(CH
2)
nthe phenyl that the COOM group replaces is not necessarily replaced by one or more substituting group, described substituting group be F, Cl, Br ,-(CH
2)
ncOOM, R ,-CF
3,-NO
2,-CN ,-NH
2,-NHR ,-NRR ' ,-NHCOR ,-NHCONHR ,-NHCONRR ' ,-NHCO (CH
2)
nnH
2,-NHSO
2r ,-OH ,-OR ,-OCOR ,-OCO (CH
2)
nnH
2,-OCONHR ,-OCONRR ' ,-OSO
2r ,-COR ,-CONHR ,-CONRR ' ,-CO (CH
2)
nnH
2,-SO
2nH
2,-SO
2nHR ,-SO
2nRR ' or-S (O)
er, the integer that wherein n is 0-6, e be 0,1,2 or 3, R, R ', M as general formula (II-7), defined;
(5) not necessarily, under alkaline condition, the compound shown in general formula (II-7-i) and reagent W-R
2and W-R
3nucleophilic substitution reaction occurs and generate the compound shown in general formula (II-7-ii), wherein, W means Cl or Br;
R
2and R
3except not defining identical for H with general formula (II-7).
Described aprotic polar solvent is selected from one or more in methyl-sulphoxide, DMF, methylene dichloride, trichloromethane, tetrahydrofuran (THF) and dioxane ethylene glycol bis methyl ether;
Described oxygenant be selected from two hydration sodium dichromate 99s, potassium bichromate, chromium trioxide, pyridinium dichromate, pyridinium chloro-chromate, ruthenium tetroxide, ceric ammonium nitrate, chromium trioxide two pyridinium salts and TEMPO-trichloroisocyanuric acid complex reagent one or more (wherein, TEMPO is 2,2,6,6-tetramethyl piperidine nitrogen oxygen free radical);
The alkali that described alkaline condition is used can be selected from one or more in imidazoles, triethylamine, pyridine, salt of wormwood, n-Butyl Lithium, sodium carbonate, NaH and KH.
Described " pharmacy acceptable salt " is the salt that forms of the mineral acids such as aniline group in molecule and hydrochloric acid, Hydrogen bromide, sulfuric acid, phosphoric acid, sodium pyrosulfate, Sodium phosphate dibasic, SODIUM PHOSPHATE, MONOBASIC or the salt formed with organic acids such as formic acid, acetic acid, picric acid, methylsulfonic acid, propionic acid, oxalic acid, propanedioic acid, succsinic acid, fumaric acid, toxilic acid, lactic acid, oxysuccinic acid, tartrate, citric acids, also comprises in molecule-(CH
2)
nthe salt that COOM group and mineral alkali form, as sodium, potassium, calcium, aluminium salt and ammonium salt, or the salt formed with organic bases, as methylamine salt, ethylamine salt, ethanolamine salt etc.
The present invention also provides the application in the medicine for the preparation for the treatment of human reproductive system tumour of the tripterygium wilfordii diterpenes diterpenoids lactones derivative shown in general formula (I) and pharmacy acceptable salt or hydrate thereof, wherein, the tripterygium wilfordii diterpenes diterpenoids lactones derivative of telling and pharmacy acceptable salt thereof or hydrate with the amount of 0.001-30mg/kg, be used.
In pharmaceutical composition according to the present invention, the content of described tripterygium wilfordii diterpenes diterpenoids lactones derivative and pharmacy acceptable salt thereof or hydrate is 0.001～99.9wt%.
The formulation of pharmaceutical composition of the present invention can be the formulation through gastrointestinal administration or non-through the gastrointestinal administration formulation.The described formulation through gastrointestinal administration can be solution, emulsion, tablet, capsule etc.Described parenteral administration dosage can be injection, comprises the injecting pathways such as intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection; Through percutaneous drug delivery, as external-use lotion, ointment, patch etc.; Mucosal, as hypogloeeis, nasal cavity, rectum, vagina, duct etc.
The active ingredient tripterygium wilfordii diterpenes diterpenoids lactones derivative of pharmaceutical composition of the present invention and pharmacy acceptable salt thereof or hydrate can be by single medications, also can with other antitumor drug combination therapy.Therefore, pharmaceutical composition of the present invention may further include one or more other antitumor drugs, and described antitumor drug is for affecting the biosynthetic medicine of tumour cell nucleic acid; Directly destroy the medicine that DNA of tumor cell stops it to copy; Embed the medicine that disturbs transcription in DNA of tumor cell; Disturb mitotic division to affect the medicine of tumour cell protein synthesis; Or by suppressing the medicine of cyclooxygenase (COX-2) generation antitumor action.Wherein, the described biosynthetic medicine of tumour cell nucleic acid that affects can be 5 FU 5 fluorouracil (5-Fluorouracil), mercaptopurine (6-Mercaptopurine), methotrexate (Methotrexate), cytosine arabinoside (Cytarabine) and hydroxyurea (Hydroxyurea) etc., the medicine that described direct destruction DNA of tumor cell stops it to copy can be mustargen (Chlormethine Hydrochloride), endoxan (Cytoxam), thiophene is for sending (Thiotepa), busulfan (Busulfan), ametycin (Mitomycin C), bleomycin (Bleomycin), cis-platinum (Cisplatin), ormaplatin (OP), RP-54780 (Oxaloplatin), DWA2114R, CI-973, lobaplatin (Lobaplatin), camptothecine (Camptothecin), Etoposide (Etoposide) etc., disturbing the medicine of transcription in described embedding DNA of tumor cell can be dactinomycin (Actinomycin D), Zorubicin (ADM), darubicin (Idarubicin) and mitoxantrone (NVT), SN-11841 (mAMSA) etc., described interference mitotic division affects the medicine of tumour cell protein synthesis can be for as vinealeucoblastine(VLB) (VLB) and vincristine(VCR) (VCR), carbon vinealeucoblastine(VLB) (VRB), taxol (Taxol), taxotere (Taxotere), ASP (L-asparaginase) or harringtonine (Harringtonine) etc., the described medicine that produces antitumor action by suppressing cyclooxygenase (COX-2) can be acetylsalicylic acid (Aspirin), indomethacin (Indomethaein), Ibuprofen BP/EP (Spansule Capsulae Ibuprofeni), nimesulide (Nimesulide), celecoxib (Celecoxib), rofecoxib (Rofecoxib), the medicine that described inhibition tumour neovascularity generates can be micromolecular compound Sutent (sunitinib), Xarelto (sorafenib), rapamycin (rapamycin) and antibody Arastin (bevacizumab) etc., described angiolysis medicine can be combretastatin (combretastatin A4), dimethylbenzene pyrrole acid (5,6-Dimethylxanthenoneacetic acid, DMXAA) etc., described tyrosine kinase inhibitor can be the antitumor drugs such as micromolecular compound imatinib (imatinib), erlotinib (erlotinib), Gefitinib (gefitinib), lapatinibditosylate (lapatinib) and antibody Erbitux (cetuximab), Trastuzumab (trastuzumab).
During treated with combined medication, triptolide alcohol derivative and pharmacy acceptable salt thereof or hydrate and other chemotherapeutics can be administrations simultaneously, can be sequential administration, can be also separately administrations.
The present invention also provide aforementioned pharmaceutical compositions for the preparation of the treatment tumour and with the medicine of the disease of Tumor-assaciated in application, wherein, medicine activity component is used with the amount of 0.001～30mg/kg.
Pharmaceutical composition of the present invention can be used for the treatment of the warm-blooded animal that suffers from the proliferative diseases such as tumour, and described " tumour " comprises innocent tumour and malignant tumour: innocent tumour mainly contains fibroma, lipoma, vascular tumor etc.; Malignant tumour mainly comprises that the malignant tumour occurred by epithelium is as squamous cell carcinoma, mammary cancer, ovarian cancer etc., by the histogenetic malignant tumour of mesoderm as fibrosarcoma, osteosarcoma, lymphosarcoma, neurospongioma etc., and by the histogenetic malignant tumour of embryonic cell, neurocyte or prematurity and the malignant tumour that occurred by hematopoietic cell etc.Be particularly useful for treatment the conventional cell cytotoxic drug is had to drug-fast tumour as Zorubicin, taxol, docetaxel, vinorelbine etc., the tumour with multidrug resistance particularly mediated by P-170 glycoprotein.Described " warm-blooded animal " comprises people and other animal, as rodent and mammal.The implication of described " proliferative disease " comprises tumour, atypical hyperplasia, but is not limited to tumour and atypical hyperplasia.
Pharmaceutical composition of the present invention can also, for the disease with Tumor-assaciated, comprise the tumor diseases such as mammary cancer of the tumour with multidrug resistance of prostate cancer, human ovarian cancer, cancer of the stomach, myelocytic leukemia, colorectal carcinoma, mammary cancer, the mediation of P-170 glycoprotein as the anti-medicine of Zorubicin.
Beneficial effect
(application number: difference 200910048699.8) is, the substituent structure difference on C14 has been introduced contain-(CH on the C14 position in the application of the first submit of the application and applicant
2)
nthe phenyl amines small molecules side chain that the COOM group replaces, make compound be easy to and various mineral acids and organic acid salify, and in molecule-(CH
2)
nthe COOM group is easy and mineral alkali or organic bases salify also, and this will improve the water-soluble of compound greatly.The effect experiment aspect, LLDT-223, LLDT-224 and LLDT-225 show very potent cytotoxicity.
The present invention has synthesized tripterygium wilfordii diterpenes diterpenoids lactones derivative efficient, low toxicity, can be practically for the treatment of tumor disease.External drug effect result shows, although LLDT-223, LLDT-224 and LLDT-225 will think the C14 β-OH of essential groups and change C14 α-OH in the past, but still show very strong antitumor action, this provides larger development space for the direction of structure of modification undoubtedly, therefore makes drug regimen of the present invention have better application prospect.
Embodiment
Below in conjunction with example, the present invention is further elaborated, but these embodiment are never any limitation of the invention, scope of the present invention is determined by claim.
preparation Example
Instrument and main experiment material are as follows:
BrukerAM-400 type and Varian Mercury plus-400 type nuclear magnetic resonance analyser, MAT-711 and MAT-95 type mass spectrograph, H and 200-300 order column chromatography silica gel (Haiyang Chemical Plant, Qingdao), HSGF254TLC plate (Yantai City chemical research institute).
Starting raw material: the method preparation of describing in document [1] for Triptonide (LLDT-1).
Document [1]: Zhou, B.; Li, X.M.; Feng H.J.; Li, Y.C.Tetrahedron 2010,66, and 5396.
Preparation Example 1 compound (3)
Under argon shield, the 50mL anhydrous tetrahydro furan is added in the reaction flask that is placed with magnesium chips (900mg, 37.5mmol), chloromethyl dimethyl isopropoxy silane (6mL) is added drop-wise in reaction system through constant pressure funnel.Finish this lead reaction system and stir 30min under 50 ℃, prepared grignard reagent.The grignard reagent that this is prepared dropwise adds in the Triptonide (LLDT-1) (3g, 8.4mmol) that has been dissolved in the 100mL dry tetrahydrofuran.Stopped reaction after reaction 1.5h under room temperature, reaction system saturated ammonium chloride solution cancellation, the ethyl acetate extraction, organic layer saturated common salt water washing, anhydrous sodium sulfate drying, obtain thick product compound (2) after concentrating.Without further purifying, compound (2) is dissolved in 50mL methyl alcohol and 80mL tetrahydrofuran (THF), add KHCO
3(3.5g), KF (3.9g) and 30% hydrogen peroxide (10mL), react and add the sodium sulfite solution that 10ml is saturated after 3 hours, by the organic solvent evaporated under reduced pressure, add ethyl acetate and saturated aqueous common salt extraction, organic layer saturated common salt water washing, anhydrous sodium sulfate drying, the thick product after concentrating is through column chromatography purification (eluent: ethyl acetate: hexanaphthene=1: 2) obtain white solid compound (3) (2.28g, productive rate: 70%).
Compound 3:
1h NMR (CDCl
3, 300MHz) δ 4.67 (s, 2H), 4.26 (d, J=11.8Hz, 1H), 3.87-3.80 (m, 2H), (3.64 d, J=11.5Hz, 1H), 3.46 (d, J=3.3Hz, 1H), 2.76-2.64 (m, 1H), (2.45 sept., J=6.9Hz, 1H), 2.37-2.25 (m, 1H), 2.23-2.04 (m, 2H), 1.89 (t, J=14.1Hz, 1H), 1.55 (dd, J=12.6,5.2Hz, 1H), 1.25-1.13 (m, 1H), (1.07 s, 3H), 0.91 (d, J=6.9Hz, 3H), 0.89 (d, J=6.9Hz, 3H);
13c NMR (CDCl
3, 100MHz) δ 173.2 (C), 160.2 (C), 125.4 (C), 74.4 (C), 70.0 (CH
2), 67.5 (C), 65.3 (C), 65.2 (CH
2), 65.0 (C), 56.5 (CH), 56.1 (CH), 54.4 (CH), 40.3 (CH), 36.0 (C), 30.1 (CH
2), 25.5 (CH), 23.4 (CH
2), 20.9 (CH
3), 18.6 (CH
3), 17.1 (CH
2), 13.7 (CH
3); IR (KBr) 3415,3361,2966,2927,2875,1755,1724,1672,1439,1074,1018cm
-1; MS (EI, 70eV) m/z (%) 391 ([M+1]
+, 2), 372 (1), 71 (100); HRMS (EI) calcd.for C
21h
27o
7(M+H)
+391.1757, found 391.1752.Anal. (C
21h
26o
7) C, H.
Preparation Example 2 compounds (4)
By compound 3 (420mg, 1.08mmol) be dissolved in the 15mL dichloromethane solvent, add trichloroisocyanuric acid (376mg in 0 ℃, 1.62mmol), add afterwards TEMPO (16mg, 0.108mmol) and with TLC, detect rapidly, react completely and add the sodium carbonate solution cancellation to react and regulate the pH value to neutral, use dichloromethane extraction, organic phase is water, saturated common salt water washing respectively, and concentrated after anhydrous sodium sulfate drying, column chromatographic isolation and purification obtains white solid compound 4 (340mg, 0.87mmol, productive rate: 81%).
Compound 4:
1h NMR (CDCl
3, 300MHz) δ 10.03 (s, 1H), 4.76-4.59 (m, 2H), 3.97 (d, J=3.0Hz, 1H), (3.91 s, 1H), 3.75 (d, J=5.9Hz, 1H), 3.60 (d, J=3.0Hz, 1H), (2.79-2.67 m, 1H), 2.38-2.26 (m, 1H), (1.87 dd, J=14.7,13.6Hz, 1H), 1.58 (dd, J=12.6,4.0Hz, 1H), 1.03 (s, 3H), (0.83 d, J=6.9Hz, 3H), (0.79 d, J=6.9Hz, 3H);
13c NMR (CDCl
3, 100MHz) δ 198.3,173.2, and 160.1,125.4,81.7,69.9,65.9,65.5,62.1,56.3,55.8,54.0,40.4,36.0,30.2,26.6,23.3,19.8,17.3,17.1,13.6; IR v
max(KBr) 3448,2968,2933,2875,2254,1747,1728,1674cm
-1; MS (EI, 70eV) m/z (%) 389 ([M+1]
+, 4), 388 (M
+, 1), 371 (2), 343 (6), 327 (52), 299 (88), 71 (100).
Preparation Example 3 (14S)-14 β-N-(2 '-the methoxycarbonyl phenyl)-aminomethyl Epitriptolide (LLDT-221)
By compound 4 (39mg, 0.1mmol) be dissolved in the 4mL acetonitrile solvent, add 2-Methyl anthranilate (15.1mg, 0.1mmol), stirring at room 0.5h, add afterwards sodium triacetoxy borohydride (42mg, 0.2mmol), after reacting 4h under room temperature, stopped reaction, most of solvent decompression is steamed, after the residue thin up, be extracted with ethyl acetate, organic phase is water and saturated common salt water washing respectively, concentrated after anhydrous sodium sulfate drying, column chromatographic isolation and purification obtains white solid compound (14S)-14 β-N-(2 '-methoxycarbonyl phenyl)-aminomethyl Epitriptolide (LLDT-221) (15.7mg, productive rate: 30%).
LLDT-221:
1h NMR (CDCl
3, 300MHz) δ 7.92 (d, J=8.1Hz, 1H), 7.42-7.36 (m, 1H), 6.97 (d, J=8.1Hz, 1H), 6.69 (t, J=8.1Hz, 1H), 4.67 (s, 2H), 3.96-3.81 (m, 6H), 3.50 (d, J=2.7Hz, 1H), 3.08 (s, 1H), 2.78-2.68 (m, 1H), 2.55 (sept, J=6.9Hz, 1H), 2.37-2.12 (m, 3H), 1.94 (t, J=13.5Hz, 1H), 1.57 (dd, J=11.4, 4.2Hz, 1H), 1.25-1.12 (m, 1H), 1.13 (s, 3H), 1.01 (d, J=6.9Hz, 3H), 0.93 (d, J=6.9Hz, 3H),
13c NMR (CDCl
3, 100MHz) δ 173.3,168.9, and 160.5,151.6,134.7,131.6,125.3,116.3,112.5,111.8,73.9,70.0,68.6,65.3,64.2,56.2,55.5,54.4,51.7,49.2,40.5,36.0,29.9,25.7,23.6,21.1,18.7,17.1,13.6, MS (EI, 70eV) m/z (%) 523 (M
+, 1), 164 (100), HRMS (EI) C
29h
33nO
8(M
+) calculated value: 523.2206, measured value: 523.2187.
Preparation Example 4 (14S)-14 β-N-(3 '-the methoxycarbonyl phenyl)-aminomethyl Epitriptolide (LLDT-222)
By compound 4 (39mg, 0.1mmol) be dissolved in the 4mL acetonitrile solvent, add 3-Methyl anthranilate (15.1mg, 0.1mmol), stirring at room 0.5h, add afterwards sodium triacetoxy borohydride (42mg, 0.2mmol), after reacting 4h under room temperature, stopped reaction, most of solvent decompression is steamed, after the residue thin up, be extracted with ethyl acetate, organic phase is water and saturated common salt water washing respectively, concentrated after anhydrous sodium sulfate drying, column chromatographic isolation and purification obtains white solid compound (14S)-14 β-N-(3 '-methoxycarbonyl phenyl)-aminomethyl Epitriptolide (LLDT-222) (15.7mg, productive rate: 30%).
LLDT-222:
1h NMR (CDCl
3, 300MHz) δ 7.48-7.40 (m, 2H), 7.26 (t, J=7.8Hz, 1H), 6.96-6.91 (m, 1H), 4.67 (s, 2H), (4.50 brs, 1H), 3.94-3.81 (m, 6H), (3.57 s, 1H), 3.52-3.47 (m, 2H), (2.76-2.66 m, 1H), 2.51 (sept, J=6.9Hz, 1H), 2.36-2.12 (m, 3H), 1.89 (t, J=13.5Hz, 1H), 1.56 (dd, J=12.0,5.4Hz, 1H), 1.26-1.13 (m, 1H), (1.09 s, 3H), 1.00 (d, J=6.9Hz, 3H), 0.93 (d, J=6.9Hz, 3H);
13c NMR (CDCl
3, 100MHz) δ 173.2,167.1, and 160.3,148.0,131.0,129.3,125.3,120.2,118.7,115.2,73.5,69.9,68.1,65.2,64.5,56.1,55.8,54.5,52.1,49.8,40.3,36.0,29.9,25.7,23.4,21.1,18.8,17.1,13.6; MS (EI, 70eV) m/z (%) 523 (M
+, 4), 164 (100); HRMS (EI) C
29h
33nO
8(M
+) calculated value: 523.2206, measured value: 523.2208.
Preparation Example 5 (14S)-14 β-N-(3 '-methoxycarbonyl-4 '-hydroxy phenyl)-aminomethyl Epitriptolide (LLDT-223)
By compound 4 (39mg, 0.1mmol) be dissolved in the 4mL acetonitrile solvent, add 2-hydroxyl-5-Methyl anthranilate (16.7mg, 0.1mmol), stirring at room 0.5h, add afterwards sodium triacetoxy borohydride (42mg, 0.2mmol), after reacting 4h under room temperature, stopped reaction, most of solvent decompression is steamed, after the residue thin up, be extracted with ethyl acetate, organic phase is water and saturated common salt water washing respectively, concentrated after anhydrous sodium sulfate drying, column chromatographic isolation and purification obtain white solid compound (14S)-14 β-N-(3 '-methoxycarbonyl-4 '-hydroxy phenyl)-aminomethyl Epitriptolide (LLDT-223) (32.3mg, productive rate: 60%).
LLDT-223:
1h NMR (CDCl
3, 300MHz) δ 10.26 (s, 1H), 7.24 (d, J=2.4Hz, 1H), 7.00-6.96 (m, 1H), 6.88 (d, J=8.7Hz, 1H), 4.67 (s, 2H), 4.08-3.81 (m, 8H), 3.50 (d, J=3.3Hz, 1H), 3.31 (d, J=13.5Hz, 1H), 2.76-2.66 (m, 1H), 2.47 (sept, J=6.9Hz, 1H), 2.36-2.12 (m, 3H), 1.88 (t, J=14.1Hz, 1H), 1.55 (dd, J=12.3, 4.8Hz, 1H), 1.25-1.12 (m, 1H), 1.09 (s, 3H), 0.98 (d, J=6.9Hz, 3H), 0.93 (d, J=6.9Hz, 3H),
13c NMR (CDCl
3, 100MHz) δ 173.2,170.1, and 160.3,155.9,139.3,125.3,124.9,118.4,115.2,112.1,73.0,69.9,68.1,65.2,64.7,56.3,55.9,54.5,52.3,51.6,40.3,36.0,30.0,25.7,23.4,21.2,18.8,17.1,13.7, MS (EI, 70eV) m/z (%) 539 (M
+, 23), 180 (100), HRMS (EI) C
29h
33nO
9(M
+) calculated value: 539.2156, measured value: 539.2166.
Preparation Example 6 (14S)-14 β-N-(2 '-methoxycarbonyl-4 '-hydroxy phenyl)-aminomethyl Epitriptolide (LLDT-224)
By compound 4 (39mg, 0.1mmol) be dissolved in the 4mL acetonitrile solvent, add 2-amino-5-methyl hydroxybenzoate (16.7mg, 0.1mmol), stirring at room 0.5h, add afterwards sodium triacetoxy borohydride (42mg, 0.2mmol), after reacting 4h under room temperature, stopped reaction, most of solvent decompression is steamed, after the residue thin up, be extracted with ethyl acetate, organic phase is water and saturated common salt water washing respectively, concentrated after anhydrous sodium sulfate drying, column chromatographic isolation and purification obtain white solid compound (14S)-14 β-N-(2 '-methoxycarbonyl-4 '-hydroxy phenyl)-aminomethyl Epitriptolide (LLDT-224) (32.3mg, productive rate: 60%).
LLDT-224:
1h NMR (CDCl
3, 300MHz) δ 7.40 (d, J=2.4Hz, 1H), (7.03-6.90 m, 2H), 4.67 (s, 2H), (3.86-3.79 m, 6H), 3.61 (d, J=14.4Hz, 1H), 3.49 (d, J=3.0Hz, 1H), (2.76-2.66 m, 1H), 2.51 (sept, J=6.9Hz, 1H), 2.36-2.10 (m, 3H), 1.90 (t, J=13.2Hz, 1H), 1.55 (dd, J=11.1,3.6Hz, 1H), 1.25-1.12 (m, 1H), (1.11 s, 3H), 1.00 (d, J=6.9Hz, 3H), 0.92 (d, J=6.9Hz, 3H);
13c NMR (CDCl
3, 100MHz) δ 173.6,168.4, and 160.8,147.0,145.8,125.2,123.1,116.8,115.1,113.0,73.5,70.1,68.7,65.3,64.3,56.4,55.5,54.4,51.9,50.6,40.4,36.0,29.9,25.6,23.5,21.1,18.7,17.1,13.6; MS (EI, 70eV) m/z (%) 539 (M
+, 15), 342 (100), 180 (60); HRMS (EI) C
29h
33nO
9(M
+) calculated value: 539.2156, measured value: 539.2158.
Preparation Example 7 (14S)-14 β-N-(3 '-amino-5 '-the methoxycarbonyl phenyl)-aminomethyl Epitriptolide (LLDT-225)
By compound 4 (39mg, 0.1mmol) be dissolved in the 4mL acetonitrile solvent, add 3, 5-diamino-methyl benzoate (16.6mg, 0.1mmol), stirring at room 0.5h, add afterwards sodium triacetoxy borohydride (42mg, 0.2mmol), after reacting 4h under room temperature, stopped reaction, most of solvent decompression is steamed, after the residue thin up, be extracted with ethyl acetate, organic phase is water and saturated common salt water washing respectively, concentrated after anhydrous sodium sulfate drying, column chromatographic isolation and purification obtain white solid compound (14S)-14 β-N-(3 '-amino-5 '-the methoxycarbonyl phenyl)-aminomethyl Epitriptolide (LLDT-225) (32.3mg, productive rate: 60%).
LLDT-225:
1h NMR (CDCl
3, 300MHz) δ 6.84-6.79 (m, 2H), 6.26 (s, 1H), 4.66 (s, 2H), 4.12-3.79 (m, 7H), 3.49 (d, J=3.0Hz, 1H), (3.45 d, J=12.9Hz, 1H), 2.74-2.64 (m, 1H), 2.49 (sept, J=6.9Hz, 1H), (2.36-2.12 m, 3H), 1.87 (t, J=13.5Hz, 1H), 1.55 (m, 1H), 1.25-1.12 (m, 1H), 1.07 (s, 3H), (0.98 d, J=6.9Hz, 3H), (0.92 d, J=6.9Hz, 3H);
13c NMR (CDCl
3, 100MHz) δ 173.3,167.2, and 160.4,149.1,147.5,131.9,125.3,107.3,106.1,104.8,73.5,69.9,68.2,65.2,64.5,56.1,55.7,54.5,52.0,49.7,40.3,36.0,29.9,25.6,23.4,21.1,18.8,17.1,13.6; MS (EI, 70eV) m/z (%) 538 (M
+, 8), 342 (22), 179 (100); HRMS (EI) C
29h
34n
2o
8(M
+) calculated value: 538.2315, measured value: 538.2321.
Preparation Example 8 (14S)-14 β-N-(2 '-methoxycarbonyl-4 '-fluorophenyl)-aminomethyl Epitriptolide (LLDT-232)
By compound 4 (39mg, 0.1mmol) be dissolved in the 4mL acetonitrile solvent, add 2-amino-5-fluorobenzoic acid methyl esters (16.6mg, 0.1mmol), stirring at room 0.5h, add afterwards sodium triacetoxy borohydride (42mg, 0.2mmol), after reacting 4h under room temperature, stopped reaction, most of solvent decompression is steamed, after the residue thin up, be extracted with ethyl acetate, organic phase is water and saturated common salt water washing respectively, concentrated after anhydrous sodium sulfate drying, column chromatographic isolation and purification obtain white solid compound (14S)-14 β-N-(2 '-methoxycarbonyl-4 '-fluorophenyl)-aminomethyl Epitriptolide (LLDT-232) (32.3mg, productive rate: 60%).
LLDT-232:
1h NMR (CDCl
3, 300MHz) δ 7.78 (brs, 1H), 7.61 (dd, J=9.9, 3.6Hz, 1H), 7.19-7.11 (m, 1H), 6.99-6.94 (m, 1H), 4.68 (s, 2H), 3.93-3.81 (m, 6H), 3.69-3.61 (m, 1H), 3.50 (d, J=3.0Hz, 1H), 3.14 (s, 1H), 2.79-2.69 (m, 1H), 2.51 (sept, J=6.6Hz, 1H), 2.38-2.10 (m, 3H), 1.94 (t, J=13.5Hz, 1H), 1.56 (m, 1H), 1.25-1.12 (m, 1H), 1.12 (s, 3H), 1.01 (d, J=6.6Hz, 3H), 0.93 (d, J=6.6Hz, 3H),
13c NMR (CDCl
3, 100MHz) δ 173.3,168.0, and 160.4,155.1,148.4,125.3,122.3,122.1,117.0,116.8,114.3,112.2,73.8,69.9,68.6,65.3,64.2,56.3,55.5,54.4,52.0,50.0,40.5,36.1,29.9,25.7,23.6,21.1,18.7,17.1,13.6, MS (EI, 70eV) m/z (%) 541 (M
+, 1), 182 (100), HRMS (EI) C
29h
32nFO
8(M
+) calculated value: 541.2112, measured value: 541.2121.
Preparation Example 9 (14S)-14 β-N-(2 '-hydroxyl-4 '-the methoxycarbonyl phenyl)-aminomethyl Epitriptolide (LLDT-233)
By compound 4 (39mg, 0.1mmol) be dissolved in the 4mL acetonitrile solvent, add 3-hydroxy-4-aminobenzoic acid methyl esters (16.7mg, 0.1mmol), stirring at room 0.5h, add afterwards sodium triacetoxy borohydride (42mg, 0.2mmol), after reacting 4h under room temperature, stopped reaction, most of solvent decompression is steamed, after the residue thin up, be extracted with ethyl acetate, organic phase is water and saturated common salt water washing respectively, concentrated after anhydrous sodium sulfate drying, column chromatographic isolation and purification obtain white solid compound (14S)-14 β-N-(2 '-hydroxyl-4 '-the methoxycarbonyl phenyl)-aminomethyl Epitriptolide (LLDT-233) (32.3mg, productive rate: 60%).
LLDT-233:
1h NMR (CDCl
3, 300MHz) δ 7.55 (d, J=9.0Hz, 1H), 7.53 (s, 1H), 7.27 (brs, 1H), 6.69 (d, J=8.4Hz, 1H), 4.66 (m, 2H), 3.90 (d, J=14.1Hz, 1H), 3.84 (s, 3H), 3.82 (d, J=3.3Hz, 1H), 3.77 (d, J=6.0Hz, 1H), 3.58 (d, J=14.4Hz, 1H), 3.51 (d, J=3.3Hz, 1H), 3.39 (s, 1H), 2.74-2.63 (m, 1H), 2.52 (sept, J=6.9Hz, 1H), 2.34-2.02 (m, 3H), 1.85 (t, J=14.1Hz, 1H), 1.53 (dd, J=11.7, 3.9Hz, 1H), 1.25-1.12 (m, 1H), 1.07 (s, 3H), 0.97 (d, J=6.9Hz, 3H), 0.91 (d, J=6.9Hz, 3H),
13c NMR (CDCl
3, 100MHz) δ 173.6,167.7, and 160.7,143.2,141.8,125.2,124.0,118.6,114.9,109.7,74.0,70.1,68.3,65.3,64.3,56.0,55.6,54.5,51.8,49.0,40.3,36.0,29.8,25.7,23.4,21.0,18.7,17.0,13.6, MS (EI, 70eV) m/z (%) 539 (M
+, 24), 342 (100), HRMS (EI) C
29h
33nO
9(M
+) calculated value: 539.2155, measured value: 539.2154.
Preparation Example 10 (14S)-14 β N-(2 '-hydroxyl-5 '-the methoxycarbonyl phenyl)-aminomethyl Epitriptolide (LLDT-234)
By compound 4 (39mg, 0.1mmol) be dissolved in the 4mL acetonitrile solvent, add 3,4-AHBA methyl esters (16.7mg, 0.1mmol), stirring at room 0.5h, add afterwards sodium triacetoxy borohydride (42mg, 0.2mmol), after reacting 4h under room temperature, stopped reaction, most of solvent decompression is steamed, after the residue thin up, be extracted with ethyl acetate, organic phase is water and saturated common salt water washing respectively, concentrated after anhydrous sodium sulfate drying, column chromatographic isolation and purification obtain white solid compound (14S)-14 β N-(2 '-hydroxyl-5 '-the methoxycarbonyl phenyl)-aminomethyl Epitriptolide (LLDT-234) (32.3mg, productive rate: 60%).
LLDT-234:
1h NMR (CDCl
3, 300MHz) δ 7.46 (s, 1H), 7.42 (d, J=7.5Hz, 1H), 6.82 (d, J=7.8Hz, 1H), 4.67 (s, 2H), 3.91-3.78 (m, 6H), 3.53-3.46 (m, 2H), 2.75-2.65 (m, 1H), 2.52 (sept, J=7.2Hz, 1H), (2.36-2.02 m, 3H), 1.85 (t, J=13.8Hz, 1H), 1.55 (m, 1H), 1.25-1.12 (m, 1H), 1.08 (s, 3H), (0.99 d, J=7.2Hz, 3H), (0.93 d, J=7.2Hz, 3H);
13c NMR (CDCl
3, 100MHz) δ 173.8,167.4, and 161.0,149.1,136.2,125.2,122.6,121.8,114.0,113.9,73.5,70.2,68.4,65.2,64.5,56.2,55.7,54.6,51.9,49.8,40.4,36.0,29.9,25.7,23.4,21.1,18.8,17.1,13.6; MS (EI, 70eV) m/z (%) 539 (M
+, 99), 342 (100); HRMS (EI) C
29h
33nO
9(M
+) calculated value: 539.2156, measured value: 539.2175.
The inhibited proliferation experiment of the outer tumour cell of pharmacological evaluation embodiment human body
In following examples, test-compound is provided by chemosynthesis embodiment of the present invention.
Reagent material
SK-OV-3 human oophoroma cell line and PC-3 human prostate cancer cell line are purchased from U.S. ATCC (American Type Culture Collection).
Method
Tumour cell is cultivated with RPMI 1640 or DMEM substratum (Gibco), includes 10% foetal calf serum, and culture condition is 37 ℃, 5%CO
2.Tumor cell inoculation, in the 96-orifice plate, after 24 hours, adds test-compound.Each concentration is established three multiple holes.And the solvent of establishing respective concentration contrasts and acellular zeroing hole.Test-compound is mixed with proper concn by dimethyl sulfoxide (DMSO), and in substratum, the final concentration of test-compound is 0.0001-100 μ M; In substratum, the final concentration of dimethyl sulfoxide (DMSO) is no more than 0.1%.After processing 72 hours with test-compound, discard nutrient solution, with cold Tricholroacetic Acid fixed cell.Then use sulphonyl rhodamine B (Sulforhodamine B, SRB) solution-dyed.Wash away not in conjunction with after SRB, dissolve and protein bound SRB with Tris, by microplate reader, measure the OD value under the 520nm wavelength, with following formula, calculate inhibitory rate of cell growth:
Inhibiting rate=(OD value control wells-OD value dosing holes)/OD value control wells * 100%
According to each control of the concentration rate, adopt Logit method calculation of half inhibitory concentration IC
50.
The cytotoxic effect of table one, cultured tumor cells in vitro
| Compound | Cell strain | Tumor type | IC 50(nM) | Cell strain | Tumor type | IC 50(nM) |
| LLDT-221 | SK-OV-3 | Ovarian cancer | 1539 | PC-3 | Prostate cancer | 1796 |
| LLDT-222 | SK-OV-3 | Ovarian cancer | 2150 | PC-3 | Prostate cancer | 1091 |
| LLDT-223 | SK-OV-3 | Ovarian cancer | 240 | PC-3 | Prostate cancer | 51 |
| LLDT-224 | SK-OV-3 | Ovarian cancer | 177 | PC-3 | Prostate cancer | 68 |
| LLDT-225 | SK-OV-3 | Ovarian cancer | 170 | PC-3 | Prostate cancer | 224 |
| LLDT-232 | SK-OV-3 | Ovarian cancer | 700 | PC-3 | Prostate cancer | 1300 |
| LLDT-233 | SK-OV-3 | Ovarian cancer | 5000 | PC-3 | Prostate cancer | 825 |
| LLDT-234 | SK-OV-3 | Ovarian cancer | 1000 | PC-3 | Prostate cancer | 200 |
Annotate: IC
50concentration while for testing compound, growth of tumour cell being suppressed to reach half 50%.
According to the above results, test-compound has very significantly cytotoxicity to the tumour cell of vitro culture, so novel tripterygium wilfordii diterpenes diterpenoids lactones derivative of the present invention or its pharmacy acceptable salt or hydrate can suppress the propagation of genital system tumor effectively, can be for the preparation of the medicine for the treatment of genital system tumor disease.
Claims (6)
1. tripterygium wilfordii diterpenes diterpenoids lactones derivative or its pharmacy acceptable salt shown in general formula (II-7),
Wherein,
M means Na, K, H or R;
By one-(CH
2)
nthe phenyl that the COOM group replaces is not necessarily replaced by one or more substituting group, described substituting group be F, Cl, Br ,-(CH
2)
ncOOM, R ,-CF
3,-NO
2,-CN ,-NH
2,-NHR ,-NRR' ,-NHCOR ,-NHCONHR ,-NHCONRR' ,-NHSO
2r ,-OH ,-OR ,-OCOR ,-OCONHR ,-OCONRR' ,-OSO
2r ,-COR ,-CONHR ,-CONRR' ,-SO
2nH
2,-SO
2nHR ,-SO
2nRR' or-S (O)
er, the integer that wherein n is 0-6, e is 0,1,2 or 3;
R
2, R
3be H independently of one another;
Wherein, R, R' are identical or different C
1-C
10straight or branched alkyl, C
2-C
10straight or branched thiazolinyl, C
3-C
10cycloalkyl, phenyl, thienyl, furyl, pyridyl or pyrryl.
2. tripterygium wilfordii diterpenes diterpenoids lactones derivative or its pharmacy acceptable salt shown in general formula according to claim 1 (II-7), wherein, the tripterygium wilfordii diterpenes diterpenoids lactones derivative shown in described general formula (II-7) or its pharmacy acceptable salt are (7-1) (14S)-14 β-N-(2'-methoxycarbonyl phenyl)-aminomethyl Epitriptolide
(7-2) (14S)-14 β-N-(3'-methoxycarbonyl phenyl)-aminomethyl Epitriptolide
(7-3) (14S)-14 β-N-(3'-methoxycarbonyl-4'-hydroxy phenyl)-aminomethyl Epitriptolide
(7-4) (14S)-14 β-N-(2'-methoxycarbonyl-4'-hydroxy phenyl)-aminomethyl Epitriptolide
(7-5) (14S)-14 β-N-(3'-amino-5'-methoxycarbonyl phenyl)-aminomethyl Epitriptolide
(7-6) (14S)-14 β-N-(2'-methoxycarbonyl-4'-fluorophenyl)-aminomethyl Epitriptolide
(7-7) (14S)-14 β-N-(2'-hydroxyl-4'-methoxycarbonyl phenyl)-aminomethyl Epitriptolide
(7-8) (14S)-14 β-N-(2'-hydroxyl-5'-methoxycarbonyl phenyl)-aminomethyl Epitriptolide
3. the tripterygium wilfordii diterpenes diterpenoids lactones derivative shown in the described general formula of claim 1 (II-7) or the preparation method of its pharmacy acceptable salt, is characterized in that, comprises the following steps:
Reaction stream formula (II-7)
(1) take Triptonide LLDT-1 as initiator, in aprotic polar solvent, utilize chloromethyl dimethyl isopropoxy silane and reactive magnesium to generate the C of attack triptolide after Grignard reagent
14the position carbonyl obtains compound (2);
(2) the thick product of step (1) gained can, without separation, directly generate dihydroxyl compound (3) under the oxygenizement of hydrogen peroxide;
(3) compound (3) is oxidized to compound (4) under the effect of oxygenant;
(4) by compound (4) and amino benzenes compounds
under the effect of sodium triacetoxy borohydride, reductive amination process occurs, generate the compound shown in general formula (II-7-i), at amino benzenes compounds
in, by one-(CH
2)
nthe phenyl that the COOM group replaces is not necessarily replaced by one or more substituting group, described substituting group be F, Cl, Br ,-(CH
2)
ncOOM, R ,-CF
3,-NO
2,-CN ,-NH
2,-NHR ,-NRR' ,-NHCOR ,-NHCONHR ,-NHCONRR' ,-NHSO
2r ,-OH ,-OR ,-OCOR ,-OCONHR ,-OCONRR' ,-OSO
2r ,-COR ,-CONHR ,-CONRR' ,-SO
2nH
2,-SO
2nHR ,-SO
2nRR' or-S (O)
er, wherein e be 0,1,2 or 3, R, R', M as claim 1, defined.
4. the tripterygium wilfordii diterpenes diterpenoids lactones derivative shown in general formula according to claim 3 (II-7) or the preparation method of its pharmacy acceptable salt, wherein,
Described aprotic polar solvent is selected from one or more in methyl-sulphoxide, DMF, methylene dichloride, trichloromethane, tetrahydrofuran (THF) and dioxane ethylene glycol bis methyl ether;
Described oxygenant is selected from one or more in two hydration sodium dichromate 99s, potassium bichromate, chromium trioxide, pyridinium dichromate, pyridinium chloro-chromate, ruthenium tetroxide, ceric ammonium nitrate, chromium trioxide two pyridinium salts and TEMPO-trichloroisocyanuric acid complex reagent;
The alkali that described alkaline condition is used can be selected from one or more in imidazoles, triethylamine, pyridine, salt of wormwood, n-Butyl Lithium, sodium carbonate, NaH and KH.
5. a pharmaceutical composition that is used for the treatment of tumour, it comprises one or more tripterygium wilfordii diterpenes diterpenoids lactones derivatives claimed in claim 1 or its pharmacy acceptable salt and the pharmaceutically acceptable auxiliary material for the treatment of significant quantity.
6. tripterygium wilfordii diterpenes diterpenoids lactones derivative claimed in claim 1 or its pharmacy acceptable salt purposes in the medicine for the preparation for the treatment of ovarian cancer or prostate cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105076526A CN102443044B (en) | 2010-10-14 | 2010-10-14 | N-substituted ester-containing phenyl-14 Beta-aminomethyl epitriptolide derivatives, preparation method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105076526A CN102443044B (en) | 2010-10-14 | 2010-10-14 | N-substituted ester-containing phenyl-14 Beta-aminomethyl epitriptolide derivatives, preparation method and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102443044A CN102443044A (en) | 2012-05-09 |
| CN102443044B true CN102443044B (en) | 2013-11-13 |
Family
ID=46006018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105076526A Expired - Fee Related CN102443044B (en) | 2010-10-14 | 2010-10-14 | N-substituted ester-containing phenyl-14 Beta-aminomethyl epitriptolide derivatives, preparation method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102443044B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1261602A (en) * | 1999-04-16 | 2000-08-02 | 成都地奥制药集团有限公司 | Alcohol derivative of Triperygium wilfordii lactone and its application |
| CN1511838A (en) * | 2002-12-27 | 2004-07-14 | �й���ѧԺ�Ϻ�ҩ���о��� | Triptolide alcohol derivative and its use |
| CN1753666A (en) * | 2003-02-25 | 2006-03-29 | 美国泛华医药公司 | Halogenated triptolide derivatives as immunomodulators and anticancer agents |
-
2010
- 2010-10-14 CN CN2010105076526A patent/CN102443044B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1261602A (en) * | 1999-04-16 | 2000-08-02 | 成都地奥制药集团有限公司 | Alcohol derivative of Triperygium wilfordii lactone and its application |
| CN1511838A (en) * | 2002-12-27 | 2004-07-14 | �й���ѧԺ�Ϻ�ҩ���о��� | Triptolide alcohol derivative and its use |
| CN1753666A (en) * | 2003-02-25 | 2006-03-29 | 美国泛华医药公司 | Halogenated triptolide derivatives as immunomodulators and anticancer agents |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102443044A (en) | 2012-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shi et al. | Synthesis and tumor cell growth inhibitory activity of biotinylated annonaceous acetogenins | |
| CN101481401A (en) | Tripterygium wilfordii diterpenoid lactone derivative, pharmaceutical composition thereof and use in genital system tumor resistance | |
| Wu et al. | A class of novel carboline intercalators: Their synthesis, in vitro anti-proliferation, in vivo anti-tumor action, and 3D QSAR analysis | |
| Wang et al. | Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo | |
| CN109678923A (en) | Celastrol (different) ferulic acid ester analog derivative and preparation method thereof and purposes | |
| Lei et al. | Synthesis and anti-tumor activity of 14-O-derivatives of natural oridonin | |
| Li et al. | Synthesis and discovery of a drug candidate for treatment of idiopathic pulmonary fibrosis through inhibition of TGF-β1 pathway | |
| Kletskov et al. | Synthesis and biological activity of novel comenic acid derivatives containing isoxazole and isothiazole moieties | |
| CN111848718A (en) | Tripterine nitrogenous five-membered heterocyclic derivative and preparation method and application thereof | |
| Liang et al. | Design, synthesis and bioactivity evaluation of favorable evodiamine derivative scaffold for developing cancer therapy | |
| Liu et al. | Bistachybotrysins L–V, bioactive phenylspirodrimane dimers from the fungus Stachybotrys chartarum | |
| Li et al. | Synthesis and anti-tumor activity of nitrogen-containing derivatives of the natural product diphyllin | |
| CN102443039B (en) | N-substituted amino phenyl-14 beta-(aminomethyl) triptodiolide derivative and preparation method and application thereof | |
| Luan et al. | Synthesis and structure-activity relationship of lipo-diterpenoid alkaloids with potential target of topoisomerase IIα for breast cancer treatment | |
| CN110256522A (en) | Celastrol cinnamate analog derivative and preparation method thereof and purposes | |
| Kang et al. | Discovery of a novel water-soluble, rapid-release triptolide prodrug with improved drug-like properties and high efficacy in human acute myeloid leukemia | |
| Cai et al. | Design, synthesis, and anticancer evaluation of novel andrographolide derivatives bearing an α, β-unsaturated ketone moiety | |
| Ke et al. | Synthesis and in vitro biological evaluation of novel derivatives of Flexicaulin A condensation with amino acid trifluoroacetate | |
| CN102443044B (en) | N-substituted ester-containing phenyl-14 Beta-aminomethyl epitriptolide derivatives, preparation method and use thereof | |
| Ahmadi et al. | Synthesis, biological evaluation and molecular docking studies of indeno [1, 2-c] pyrazol derivatives as inhibitors of mitochondrial malate dehydrogenase 2 (MDH2) | |
| CN102443041B (en) | N-substituted methyl phenyl-14 beta -(aminomethyl) triptodiolide derivative and preparation method and application thereof | |
| CN102443042B (en) | N-substituted methoxy-containing phenyl-14 Beta-aminomethyl epitriptolide derivatives, preparation method and use thereof | |
| CN102432622B (en) | 4-amino oxadiazole epipodophyllotoxin derivative and preparation method and application thereof | |
| Zhou et al. | Low toxic and high soluble camptothecin derivative 2–47 effectively induces apoptosis of tumor cells in vitro | |
| CN102443043B (en) | N-substituted-14 beta -(aminomethyl) triptodiolide derivative and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131113 Termination date: 20191014 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |